448results about "Skeletal/connective tissue cells" patented technology

The present invention relates to a method for producing a skin tissue model, comprising: (a) isolating and culturing fibroblasts and keratinocytes from skin tissue; (b) preparing a bioink composition for a dermal layer and a bioink composition for an epidermal layer, the bioink composition containing the isolated cells; and (c) producing a skin tissue model using the bioink composition for a dermal layer and the bioink composition for an epidermal layer.

The present invention relates to a skin regeneration composition comprising a culture medium of tonsil-derived mesenchymal stem cells, the antioxidant activity of which is enhanced by N-acetylcysteine (NAC), and to a method for preparing the same. According to the culture medium and the preparation method of the present invention, reactive oxygen species (ROS) can be effectively reduced during the culturing of tonsil-derived mesenchymal stem cells, thereby enhancing antioxidant efficacy and enabling the preparation of a composition having excellent skin regeneration effects.

Provided herein are immortalized mesenchymal stem cells comprising a replicating recombinant retrovirus. Methods for treating a cell proliferative disorder using these immortalized mesenchymal stem cells are also provided.

The present invention provides a cardiac tissue model comprising cardiac tissue having at least one lumen or central cavity, wherein the cardiac tissue model comprises at least two different cardiac tissues selected from left ventricular tissue, right ventricular tissue, atrial tissue, outflow tract tissue, atrioventricular canal tissue, sinoatrial node tissue, and atrioventricular node tissue, the central cavity can be shared by at least two different cardiac tissues, and / or at least two different cardiac tissues comprise the ability to propagate calcium signaling connections and / or tissue contractions, a method of generating such a tissue model, and the use of the tissue model for screening purposes.

The present disclosure concerns genetic modification of fibroblasts or fibroblast-derived materials (including of the fibroblasts from which the fibroblast-derived materials are derived). In specific aspects, they are modified such that they may express one or more surface markers that allow targeting to a tissue and / or organ of interest. In some aspects, they are modified such that they may lose one or more surface markers that then allow targeting to a tissue and / or organ of interest. In certain aspects, one or more surface markers are modified that then allows targeting to a tissue and / or organ of interest.

The present invention relates to a dental / medical device that comprises poly(dioxanone) (PDO or PDS), preferably has an absorbent synthetic film exhibiting a color from white to grey, and is applied in the medical and dental fields. The dental / medical device may have stem cells and graphene used for inducing tissue reconstruction and / or inducing tissue regeneration of bone defects and other connective tissues (such as gingiva, skin, cartilage, cornea, etc.). Further, the present invention relates to the use of the device for the related applications described above and a method for manufacturing the device.

A method of treating male hypogonadism in a subject in need thereof includes administering to the subject testicular organoids generated from isolated male progenitor cells. The method can be used to slow or halt the progression of age-related diseases, and increase healthspan and longevity, in hypogonadal males. The method can be used with subjects that have not or are not receiving testosterone replacement therapy. The method does not require that the subject is pre-treated with CG. The testicular organoid includes cells expressing GFRA1, VEGF, VEGFR2, PDGF-Rα, Cyp11A1, 3β-HSD, 17β-HSD, LHCGR, α-SMA, CD11b, MHC CII, CD64, CD95, Sox9, AR, inhibin β-B, and FSHR.

The application relates to the field of high polymer materials, in particular to an exosome composite material for treating periodontitis and a preparation method thereof. The exosome composite material comprises the following raw materials in parts by weight: 10-20 parts of a chitosan derivative, 10-20 parts of sodium hyaluronate, 1-5 parts of zein, 0.5-1 part of exosomes, 0.1-0.3 parts of phosphonodipeptide sodium and 60-70 parts of deionized water. The exosome composite material can inhibit periodontal pathogenic bacteria, reduce the expression of proinflammatory factors by inhibiting the signal pathways such as NF-kappa B, and thus relieve periodontal tissue inflammation.

The application provides a pulmonary artery tissue-derived cell, an organoid and a construction method and application thereof. The pulmonary artery intimal stripping tissue organoid structure obtained by the preparation method is clear, has consistent cell types as the source tissue, is close to the original tissue, is convenient for researchers to operate, and thus has good practical application value.

The application discloses a method for inducing exosomes by adopting starvation combined gradient hypoxia and the exosomes prepared by the method and application, and belongs to the technical field of biological medicine. In view of the problems of low yield and insufficient activity of the existing exosome preparation method, a gradient hypoxia domestication culture strategy is provided. The method comprises sequentially performing stage hypoxia starvation culture on seed cells under a higher oxygen concentration and a lower oxygen concentration. Through the combined gradient induction mode, the yield of exosomes can be significantly improved, which is more than 2 times that of a normal oxygen group and more than 30% that of a single hypoxia group, and the repair promotion and anti-inflammatory activity thereof is enhanced. The exosomes prepared by the application are uniform in particle size, high in purity and activity, the process is stable and controllable, and are suitable for large-scale production, and are suitable for use in the fields of regenerative medicine, drug delivery and clinical treatment.

The present disclosure provides methods and compositions for targeting lipid bilayer particles, such as secreted extracellular vesicles, and cargo entities contained therein, to recipient cells.

The application provides an individualized 3D printing exosome-siRNA loaded hydrogel scaffold system for spinal cord injury repair and application thereof, and belongs to the technical field of biological medicine. The application designs an individualized scaffold based on multi-modal imaging, and realizes printing of an exo-siRNA loaded hydrogel scaffold by using a biological 3D printer. By in-situ transplantation, the irregular broken ends are precisely matched, the gaps are bridged, and the exo-siRNA is released to act on PTEN / mTOR key molecules to promote neural network remodeling, reduce the drug dosage, and reduce the side effects of systemic administration, thereby obviously improving the prognosis and having good practical application value.

The present application relates to the technical field of biology, and particularly relates to a mesenchymal stem cell culture medium and a preparation method and application thereof.The mesenchymal stem cell culture medium comprises a basic culture medium, fetal bovine serum, basic fibroblast growth factor, polymyxin B and deionized water.The present application can simultaneously improve the proliferation activity of mesenchymal stem cells and the secretion performance of HGF by simultaneously adding the basic fibroblast growth factor and the polymyxin B in the basic culture medium; more stem cells can be in the active proliferation and division process by limiting the content of the basic fibroblast growth factor in the mesenchymal stem cell culture medium to 5-50 ng / mL; and the secretion performance of HGF can be improved while the cell proliferation activity is maintained by limiting the content of the polymyxin B in the mesenchymal stem cell culture medium to 50-100 mu g / mL.

The present invention relates to osteochondral progenitor cells derived from mammalian-derived dedifferentiated adipocytes.

The application discloses a kind of mesenchymal stem cell ball fractional dissociation digestive juice, its preparation method and application, it is related to cell preparation and three-dimensional cell culture technical field, specifically at to provide C liquid, D liquid and E liquid three kinds of gradient concentration working solution.When dissociating, the mesenchymal stem cell ball to be dissociated is determined its average particle size;According to the average particle size, select C liquid, D liquid or E liquid as digestive juice as described above;The selected digestive juice is mixed with the mesenchymal stem cell ball, and digestion reaction is carried out under oscillation condition, and single cell suspension is obtained.The application establishes the hierarchical matching rule of mesenchymal stem cell ball particle size and specific digestive juice concentration, and optimizes oscillation digestion condition, so as to maintain high activity rate and complete phenotype characteristics while efficiently dissociating, realizes the standardization of process and the controllable of dissociation quality, provides stable and reliable solution for the large-scale preparation and quality control of mesenchymal stem cell ball.

Embodiments of the disclosure include methods and compositions related to modulation of bone using particular fibroblasts. The modulation includes reducing osteoclast activity and / or activation and / or stimulating osteoblast activity. In particular cases, bone is modulated in an individual with a bone condition, such as osteoporosis. Particular fibroblasts may be delivered to reduce inflammatory cytokine production including RANK ligand.

The application discloses application of mesenchymal stem cell spheroids in preparation of a preparation for treating osteoarthritis, and relates to the technical field of cell therapy and osteoarthritis treatment, and specifically comprises mesenchymal stem cell spheroids with an average diameter of 120-180 mu m and a solution containing 0.5%-10% human serum albumin. The cells are prepared into 120-180 mu m cell spheroids, and the solution containing specific concentration human serum albumin is used as a carrier, so that the cell survival rate is stabilized at more than 90%, and high-activity delivery is realized; the optimized size ensures smooth injection and long-term retention in the joint cavity, and overcomes the shortcoming that single cells are easily removed; after joint cavity injection, the preparation can synergistically promote bone reconstruction and cartilage repair, and produces clear curative effects such as bone mass increase of more than 30%, cartilage degeneration score reduction of more than 50%, and the like, which are quantifiable and verifiable, so that a stable, long-acting and curative drug preparation and application scheme are provided for osteoarthritis treatment.

The present application relates to a kind of pluripotent stem cell co-differentiation method for generating vascularized heart organoids, the method comprises: (1) in iPSCs, obtain iEC-iPSCs by transferring exogenous gene Tet 3G and ETV2;(2) the iEC-iPSCs in step (1) are mixed with iPSCs, add culture medium I, prepare blastula after culture;(3) the blastula in step (2) is induced by using the heart organoid differentiation method combined with doxycycline, and vascularized heart organoids are prepared after differentiation culture.The present application uses Tet-on 3G inducible expression system, promotes the differentiation of part of cells in heart organoids to endothelial cell lineage by regulating the expression of ETV2 gene in part of iPSCs in blastula, and then forms vascularized heart organoids.

This invention belongs to the field of biomedical technology, specifically relating to a rapid purification method for umbilical cord MSC exosomes and their application in the preparation of drugs for treating COPD. This invention discloses a method for rapidly purifying umbilical cord mesenchymal stromal cell (MSC) exosomes and a pharmaceutical composition comprising umbilical cord MSC exosomes and yamosaponin. In this pharmaceutical composition, the umbilical cord MSC exosomes and yamosaponin synergistically enhance the dynamic compliance of COPD rats, reduce airway resistance, decrease pulmonary inflammation, and repair pulmonary dysfunction. This invention provides a new technical solution for the preparation of drugs for treating or improving COPD.

It suppresses the aging of keratinocytes, promotes the differentiation of keratinocytes, and maintains the epidermal stem cells contained in the culture. [Solution] The method for producing keratinocytes includes the steps of culturing mesenchymal stem cells on a substrate, and culturing keratinocytes on a cell culture substrate obtained by decellularizing the cultured mesenchymal stem cells.

A method for culturing a human hepatic parenchymal cell, the method comprising culturing the human hepatic parenchymal cell in a culture medium comprising a culture supernatant of a human hepatic nonparenchymal cell, a Wnt signaling promoter and a cell-division-promoting growth factor.

This invention belongs to the field of biomedicine and relates to a composition of intestinal flora regulators and mesenchymal stem cells and its application. The composition of this invention is applicable to the treatment of diabetes, effectively enhancing the therapeutic effect of mesenchymal stem cells in diabetes treatment, especially autoimmune type 1 diabetes, reducing pancreatic islet inflammation, and preserving more pancreatic β cells. It provides support for the clinical translation and application of mesenchymal stem cells and has promising application prospects.

The present invention relates to a method of identifying rejuvenating factor(s) by culturing bone marrow cells wherein age-specific human serum is added to the bone marrow cells and to a method of testing active agents to augment the effect of the one or more rejuvenating factor(s) identified.

The present invention relates to a novel method for preparing an organoid using the self-assembly of spheroid. Particularly, the organoid prepared by the preparation method of the present invention has a cup-shaped morphology with a concave center, and thus, the following advantages may be obtained: nutrients and oxygen can be smoothly supplied to the center, and limitations in the size of organoid can be overcome.

The present invention relates to a method for the preparation of an assembly of cells and microrobots comprising (a) preparing a suspension of cells and microrobots, wherein the microrobots comprises an alginate, collagen, fibrin, hyaluronic acid / collagen, polyacrylamide, or polyethylene glycol hydrogel capsule, wherein the alginate is conjugated to cell adhesive peptides, and (b) incubating the suspension of (a) to allow the microrobots to form an assembly with the cells via the binding of the cell adhesive peptides to the cells, wherein step (b) and preferably steps (a) and (b) are performed in a conic microcentrifuge tube with a rounded bottom without corners and edges.

The objective is to provide a novel method for improving the efficiency of osteogenic differentiation induction based on immobilized BMP-2. [Solution] A method for stimulating cells with ligand molecules, comprising a stimulation step of applying physical stimulation to the cells and / or ligand molecules, wherein the ligand molecule is bound to or interacts with a receptor protein expressed on the cells and is immobilized on a culture substrate and / or matrix molecule used for culturing the cells, the receptor protein mediates the transmission of extracellular signals to the cells based on its binding to the ligand molecule, and the extracellular signals are enhanced by the physical stimulation.

Provided herein are compositions and methods for treating or preventing dilated cardiomyopathy (DCM) in a subject in need thereof, e.g., through correcting one or more point mutations at the RBM20 locus using CRISPR-associated base editing.

The application discloses a mutant Cas12i nuclease and application thereof, and belongs to the technical field of gene editing. The Cas mutant protein provided by the application is a mutant protein in which the 7th, 168th, 273rd, 332nd, 478th, 505th and 551st amino acids of SEQ ID NO:1 are all mutated into arginine, and other amino acid sequences remain unchanged. The application improves the editing efficiency by mutating multiple amino acids of the wild-type Cas12i protein, and can be used for multi-gene editing.

The present invention discloses the use of Avn Anthramides C (Avn C) as an inducer of chondrocytic differentiation in Mesenchymal Stem Cells (MSCs), providing a promising approach for regenerative cartilage therapy. By employing Avn C treatment, MSCs exhibit enhanced chondrocytic differentiation and elevated expression of key specific chondrogenic extracellular matrix (ECM) factors, notably Collagen Type II (COL2A1). Furthermore, when Avn C is used in combination with Chondroitin Sulfate (CS), a synergistic effect is observed, leading to upregulation of the transcriptional activity state of SOX9, a key regulator of chondrogenesis. The disclosed invention shows significant improvements in mRNA gene expression (ACAN, LRP1, SOX9), cellular protein levels (COL2A1, SOX9, LRP1), and functional outcomes, as evidenced by the secretion of extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2, and CO3A1).

The present invention relates to methods of production, isolation and application of extracellular vesicles (EV)s derived from stem cells from human exfoliated deciduous teeth. The invention also relates to the use of said EVs in therapy, such as in the treatment of Parkinson's disease.